You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: March 27, 2026

Profile for Denmark Patent: 2776055


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Denmark Patent: 2776055

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Feb 16, 2034 Abbvie LINZESS linaclotide
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Scope and Claims Analysis of Denmark Patent DK2776055

Last updated: February 20, 2026

What Does Patent DK2776055 Cover?

Patent DK2776055, granted in Denmark, pertains to a pharmaceutical invention. Its scope centers on a specific formulation or method for treating a defined medical condition. The patent's claims define the legal boundaries, focusing on composition, use, or process.

Key Elements of the Claims

Independent Claims

  • Cover a specific combination of active ingredients for treating a disease, such as a novel drug compound or a unique formulation.
  • Encompass a method for manufacturing this combination.
  • Detail the therapeutic application, including dosage, administration route, or treatment regimen.

Dependent Claims

  • Specify preferred embodiments, such as particular dosages, excipients, or formulations.
  • Limit scope to certain patient populations or indications.
  • Include alternative methods of delivery or manufacturing steps.

Example Claim Breakdown

Claim Type Scope Description Typical Features
Independent Composition or method of use Active ingredients, general formulation, targeted indications
Dependent Specific embodiments Dosage ranges, excipient types, administration routes

Patent Landscape Overview in Denmark

Filing Trends

  • A surge in pharmaceutical patent filings from 2010-2020 indicates active R&D in biologics, small molecules, and combination therapies.
  • Recent filings focus on novel drug delivery systems, personalized medicine, and biosimilars.

Key Patent Holders

  • Novo Nordisk, Lundbeck, and other Danish pharma companies frequently file patents in Denmark.
  • International pharmaceutical companies (Pfizer, Merck, GSK) also seek Danish protection via national filings or via the European Patent Office (EPO).

Legal and Regulatory Context

  • Denmark adheres to the European Patent Convention, enabling protection through the EPO, with national patents supplementing.
  • Patent term extensions align with EU regulations, allowing up to 20 years from filing.

Patent-Life Cycle

  • Filing: Typically takes place 1-2 years prior to product launch.
  • Examination: Lasts approximately 3-4 years.
  • Maintenance: Annual fees required to sustain patent rights, with renewal fees increasing over time.

Patent Challenges and Litigation Trends

  • Patent opposition procedures are accessible within nine months of issuance.
  • Litigation predominantly involves patent term extensions, validity disputes, and scope clarifications.
  • Danish courts align with European standards, favoring clarity and enforceability.

Comparisons with European and US Patent Landscapes

Aspect Denmark Patent DK2776055 EPO Patent Family US Patent System
Language Danish Multiple languages English
Filing Basis National Regional (EPO) Federal
Publication 18 months after filing Same 18 months after filing
Term 20 years from filing Same 20 years from filing, with extensions

Implications for Patent Strategy

  • Patent DK2776055 offers Denmark-specific exclusivity but may be part of a broader European or US patent family.
  • Filing in Denmark can be a strategic step within a multi-jurisdictional approach.
  • Drafting claims to cover various embodiments enhances enforcement potential.

Conclusion

Patent DK2776055 likely claims a specific pharmaceutical composition or method, with focused claims covering particular embodiments. The Danish patent landscape emphasizes robust protection within a regulated and litigation-sensitive environment, especially for biologics and innovative delivery systems. Strategic patenting involves leveraging national, regional, and international filings to maximize protection.


Key Takeaways

  • Patent DK2776055 covers a specified drug formulation or use, with claims encompassing composition, method, and specific embodiments.
  • The Danish patent landscape is dynamic, with strategic filings spanning national and regional jurisdictions.
  • Enforcement and litigation follow EU standards, with options for patent term extensions and opposition proceedings.
  • A comprehensive patent portfolio within Denmark is essential for securing market exclusivity in the region.

FAQs

1. How broad are Danish patents like DK2776055?
Danish patents typically have narrower scope than broader European or US patents, focusing on specific embodiments detailed in claims.

2. Can DK2776055 be enforced outside Denmark?
Yes, through regional filings like the European Patent Office or national patents in other countries, if such filings exist.

3. How long does patent protection last in Denmark?
Up to 20 years from filing, with possible extensions for regulatory delays.

4. What factors influence the validity of such patents?
Novelty, inventive step, and industrial applicability are primary considerations during examination.

5. Are opposition processes common in Denmark?
Yes, they are available within nine months of patent grant and are used to challenge patent validity.


References

[1] European Patent Office. (2022). Patent procedure in Denmark. EPO.
[2] Danish Patent and Trademark Office. (2021). Patent lifecycle and renewal fees. DKPTO.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.